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The Human respiratory syncytial virus (RSV) is one of the most important viral pathogens, causing 
epidemics of acute respiratory infection (ARI), especially bronchiolitis and pneumonia, in children 
worldwide. To investigate the RSV burden in Laos, we conducted a one-year study in children <5 
years old admitted to Mahosot Hospital, Vientiane Capital, to describe clinical and epidemiological 
characteristics and predictive factors for severity of RSV-associated ARI. Pooled nasal and throat swabs 
were tested using multiplex real-time PCR for 33 respiratory pathogens (FTD® kit). A total of 383 
patients were included, 277 (72.3%) of whom presented with pneumonia. 377 (98.4%) patients were 
positive for at least one microorganism, of which RSV was the most common virus (41.0%), with a peak 
observed between June and September, corresponding to the rainy season. Most RSV inpatients had 
pneumonia (84.1%), of whom 35% had severe pneumonia. Children <3-months old were a high-risk 
group for severe pneumonia, independently of RSV infection. Our study suggests that RSV infection 
is frequent in Laos and commonly associated with pneumonia in hospitalized young children. Further 
investigations are required to provide a better overall view of the Lao nationwide epidemiology and 
public health burden of RSV infection over time.
In 2012, the World Health Organization (WHO) launched the Battle against Respiratory Viruses (BRaVe) initia-
tive in response to increasing evidence that viruses play an important role in acute respiratory infections (ARI). 
WHO emphasized the need to prioritize research to gain a better understanding of the epidemiology, pathogene-
sis, prevention and clinical management of respiratory virus infections across different populations and resource 
settings1.
Indeed, ARI are still the leading killer of children less than five years of age, accounting for ~17% of the 10.4 
million deaths worldwide2. Respiratory viruses account for approximately half of all cases of community-acquired 
pneumonia and more than 90% of bronchiolitis cases in children in low- and middle-income countries3–5. 
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Although a significant number of studies on respiratory viral infections have been published, there is still a poor 
evidence-base for understanding the impact of these infections and of potential pharmacological interventions6.
Human respiratory syncytial virus (RSV) is one of the most important respiratory viral pathogens in young 
children, frequently causing bronchiolitis and pneumonia7. Nair et al. estimated that, in 2005, 33.8 million new 
episodes of RSV-associated Acute Lower Respiratory tract Infection (ALRI) occurred worldwide in children 
younger than 5 years old, with at least 3.4 million episodes necessitating hospitalization, and 66,000 to 199,000 
deaths, 99% of which occurred in developing countries5. However, the importance of RSV-associated ALRI 
remains underestimated in many developing countries, where virology data are often not available and possibly 
hidden by bacterial pathogens, especially Streptococcus pneumoniae and Haemophilus influenzae8.
The WHO Product Development for Vaccines Advisory Committee highlighted the priority for global 
healthcare of developing an RSV vaccine9. Several candidates have been evaluated in clinical trials. However, no 
approved vaccine for RSV is yet available10, 11. For successful prevention of RSV infection, a prophylactic vaccine 
approach would be the logistically easiest approach if a safe and effective RSV vaccine was to become available, 
but epidemiological data are needed to plan implementation of a vaccine campaign.
In the Lao People’s Democratic Republic (Lao PDR, Laos), respiratory infections are poorly characterized 
with only limited data available. The first influenza surveillance system established in Lao PDR with laboratory 
diagnosis included 526 patients of all ages, including 160 (30.4%) children <5 years old, with influenza-like 
illness from January 2007 to December 2008. At least one respiratory virus was detected in 54.6% of the sam-
ples; Influenzavirus A/B was the most common virus detected and only 9 (3.5%) patients were RSV-positive12. 
Between August 2009 and October 2010, samples from 292 patients of all ages admitted to two Lao hospitals (in 
Vientiane Capital and Northern Luang Prabang Province) with ALRI were collected for respiratory pathogen 
investigations13. Human rhinovirus and RSV were the most frequent viruses detected, in 35% and 26% of patients, 
respectively. RSV was found in all age groups but was more frequent in children under 5 years old. There is thus 
a crucial need to collect information to estimate the burden of RSV in Lao PDR to guide public health policy.
The aim of this study was to describe the clinical features, epidemiology and pathogens in hospitalized chil-
dren - less than 5 years old with ARI - at a central hospital in Vientiane Capital, and to identify predictive factors 
for severity.
Methods
This prospective study was conducted in Vientiane Capital, Lao PDR, from December 2013 to December 2014 at 
Mahosot Hospital, a 365-bed primary-tertiary hospital with approximately 2,000 admissions per month. Patients 
were included in the three wards where children with acute respiratory illness would be admitted: general paedi-
atric, paediatric infectious diseases, and paediatric ICU.
Patient inclusion. All children under 5 years old admitted to these three wards were enrolled according to 
the following criteria: written parental consent to participating in the study; time from onset of symptoms <14 
days, fever (axillary temperature >38.0 °C) or history of fever, and at least one respiratory symptom (dyspnea, 
cough, rhinitis) or abnormal pulmonary auscultation on physical examination.
Data collection. Demographic, epidemiologic, clinical data and measurements were collected using a ques-
tionnaire by physicians from our research team, by interviews and consulting medical charts. The same physicians 
performed physical examination and sample collection.
Case definition. Pneumonia and severe pneumonia were defined according to WHO criteria14. Children 
who presented with cough or difficulty breathing and had fast breathing (aged 2–11 months: ≥50 breaths/min-
ute, aged 1–4 years: ≥40 breaths/minute) or chest indrawing, were classified as having pneumonia. Children who 
presented with cough or difficulty breathing and had at least one of the following criteria were classified as severe 
pneumonia: oxygen saturation <90%, while breathing room air, or central cyanosis; severe respiratory distress; 
signs of pneumonia with a general danger sign (inability to breastfeed or drink, lethargy or reduced level of con-
sciousness, convulsions, vomiting). Children <2 months old who presented with cough or difficulty breathing 
and fast breathing (≥60 breaths/min) were classified as severe pneumonia.
Pneumococcal vaccination status. Pneumococcal vaccination (PCV) was launched in Lao PDR in 
November 2013. Therefore, in our study, only children <2 years old could have had access to PCV13 vaccination 
(Pneumococcal Conjugate Vaccination against 13 pneumococcal serotypes). Children <2 years old were defined 
as ‘PCV13 received’ if they had received, as reported on their vaccination booklet, at least two doses of vaccine for 
children <1 year old (one dose is unlikely to be effective against carriage or disease in those <1 year old) and at 
least one dose for children between 1 to 2 years old.
Sample collection and laboratory assays. Nasal and throat swab specimens were collected from all 
children enrolled and placed separately in 2 × 1mL Virocult vials (viral transport medium, Sigma Virocult®, 
MWE). Virocult vials were taken to the laboratory within 2 hours at ambient temperature. The swab was immedi-
ately unloaded by strongly squeezing the swab inside the medium, against the bottom of the tube for 30 seconds 
then outside of the medium against the inner wall of the tube, to release the maximum amount of liquid from the 
swab. Media were aliquoted and stored at −80 °C before performing the laboratory assays. 100 µL of nasal swab 
and 100 µL of throat swab media were pooled together for each patient and extracted using the Cador Pathogen 
96 QIAcube HT kit (Qiagen) following the manufacturer’s instructions, with an elution of 90 µL. Extracts were 
tested for 33 pathogens using the FTD® respiratory pathogens 33 kit (Fast-track Diagnostics) which consists 
of multiplexed Taqman real-time PCRs for the detection of: Influenzavirus A; Influenzavirus B; Influenzavirus 
C; Human rhinovirus; Human coronavirus NL63, 229E, OC43, HKU1; Human parainfluenza virus 1, 2, 3, 4; 
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Human metapneumovirus A and B; Bocavirus; Human respiratory syncytial virus A and B; Human adenovirus; 
Human enterovirus; Human parechovirus; Cytomegalovirus; Mycoplasma pneumoniae; Chlamydia pneumoniae; 
Staphylococcus aureus; Streptococcus pneumoniae; Haemophilus influenzae; Haemophilus influenzae type b; 
Pneumocystis jirovecii; Bordetella spp.; Moraxella catarrhalis; Klebsiella pneumoniae; Legionella spp.; Salmonella 
spp. The real-time PCR assays were considered as positive if the cycle threshold (Ct) value was <35.
Statistical analysis. For patient descriptions, we compared RSV-positive with RSV-negative patients within 
two groups of patients: all ARI patients and ARI patients with pneumonia. For the assessment of predictive fac-
tors for severity, patients with severe outcomes were compared with patients with no severe outcome within 6 
groups of patients: all ARI patients, RSV-positive ARI patients, RSV-negative ARI patients, and those same three 
Figure 1. Distribution of ARI patients, with or without pneumonia, by age groups according to RSV status.  
(A) Proportion of pneumonia among ARI patients. (B) Proportion of severe pneumonia among ARI patients 
with pneumonia.
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Characteristics n (%)
Demographic
 Age (months), median (IQR) 13 (5–22)
 Age groups
  Less than 1-month-old 14 (3.7)
  1 to less than 3-month-old 42 (11.0)
  3 –month-old to less than 1-year-old 121 (31.6)
  1 to less than 2-year-old 119 (31.1)
  2 to less than 3-year-old 49 (12.8)
  3 to less than 4-year-old 27 (7.0)
  4 to less than 5-year-old 11 (2.9)
 Gender (Male) 219 (57.2)
 Birth weight (g), median (IQR) 3,000 (2,700–3,400)
  Low birth weight347¥ 46 (13.3)
 Wards
  ICU 58 (15.1)
  Paediatric Infectious Disease 58 (15.1)
  General paediatric 267 (69.7)
 Season (Wet season*) 256 (66.8)
 PCV13 received268 ♯ 143 (53.4)
Clinical presentation
 Duration of illness prior to hospitalization (day), median (IQR) 3 (2–5)
 Fever documented at enrolment381 235 (61.7)
 Cough381 368 (96.6)
 Difficulty breathing375 275 (73.3)
 Coryza380 339 (89.2)
 Diarrhea372 155 (41.7)
 Conjunctival suffusion361 12 (3.3)
 Convulsions378 40 (10.6)
 Rigors328 34 (10.4)
 Vomiting374 208 (55.6)
Physical examination
 Chest indrawing378 216 (57.1)
 Nasal flaring371 86 (23.2)
 Lymphadenopathy359 21 (5.8)
 Abnormal pulmonary auscultation366 258 (70.5)
 Tachypnea364 171 (47.0)
 Oxygen saturation <90% in room air342 47 (13.7)
 Rash366 24 (6.6)
 Respiratory distress367 108 (29.4)
 Central cyanosis372 46 (12.4)
 Wheeze369 113 (30.6)
 Stridor365 16 (4.4)
 Grunting369 18 (4.9)
 Inability to drink368 45 (12.2)
 Prostration or lethargy368 27 (7.3)
Outcomes
 Pneumonia 277 (72.3)
 Severe pneumonia 138 (36.0)
 Length of stay ≤ 5 days376 305 (81.1)
 Supplementary oxygen used378 69 (18.3)
 Death 5 (1.3)
Detection of:
 S. pneumoniae 213 (55.6)
 H. influenzae 204 (53.3)
 Influenzavirus 29 (7.6)
 Human parainfluenza virus 37 (9.7)
Continued
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groups in patients less than 2-year old. Death, stay in ICU, oxygen use and severe pneumoniae were considered 
as indicators for severity. However, the mortality rate was too low to be analyzed and the analyses of ICU stay and 
oxygen use did not provide any added-value, so ultimately severe pneumonia alone was analyzed as an indicator 
of severe outcome. Data were double entered into an Access database (Microsoft Corporation). Statistical analysis 
was performed using Statistical Package for the Social Sciences version 23.0 for Windows (SPSS Inc., Chicago, IL, 
USA). For comparison of categorical data, the Pearson Chi-square (χ2) test and Fisher’s exact test were used as 
appropriate. The ANOVA test was applied to compare continuous variables. We fitted a binary logistic regression 
model, including a stepwise selection procedure, to assess predictive factors for severity. The level of significance 
was set at p < 0.05.
Ethics. The study was approved by the National Ethics Committee for Health Research, Ministry of Health, 
Lao PDR, and the Oxford Tropical Research Ethics Committee. Methods were carried out in accordance with 
the relevant guidelines and regulations. Informed signed consent was obtained from their legal guardians for all 
children included in this study.
Results
ARI patient characteristics. To cover the potential seasonal variability of different agents, we included 
patients over a full year from 19 December 2013 to 31 December 2014. 407 patients were included. Twenty-
four patients were excluded because of missing questionnaires or specimens. Thus, 383 patients with ARI were 
included in the final analysis, with a sex ratio (M:F) of 1.3. The median age was 13 months (IQR 5–22 months) 
(Table 1). Two hundred and seventy-seven (72.3%) patients had pneumonia. The age group with the highest 
proportion of pneumonia was that including those younger than one year (85.3%) (Fig. 1). Among patients <2 
years old, 143 (53.4%) had received PCV13. Vaccinated children were significantly more frequent in the less than 
1-year-old age group (61.3%) than in the 1 to <2-year-old age group (42.5%, p = 0.002, Figure S1). During the 
one-year study period, 5 in hospital deaths were reported, with three patients being <1 year old. All fatalities were 
diagnosed with severe pneumonia according to the WHO criteria.
Pathogen detection. Among the 383 children included, 377 (98.4%) were positive by real-time PCR for at 
least one pathogen. 321 (83.8%) of patients included were positive for respiratory viruses, RSV was detected in 
157 (41.0%). One hundred and forty-seven (93.6%) RSV-positive samples were also positive for at least one other 
microorganism, 77 (49.0%) for other respiratory viruses, and 144 (91.7%) for bacteria.
Of the RSV-positive ARI children, a complete list of viruses co-detected is provided as supplemental data 
(Table S1). Co-detection with viruses known to be frequent causes of acute respiratory infection were observed: 
Human rhinovirus in 12 (7.6%), Human adenovirus in 6 (3.8%), Human parainfluenza virus in 3 (1.9%), 
Influenzavirus in 1 (0.6%). Human metapneumovirus was not detected in any RSV-positive patients. The main 
bacterial species co-detected with RSV were S. pneumoniae and H. influenzae in 98 (62.4%) and 84 (53.5%), 
respectively.
Characteristics of ARI patients positive for RSV. The demographic and clinical features of the 157 RSV 
patients are shown in Table 2. Over half of the RSV patients (52.2%) were less than one year old, 87.9% were less 
than 2 years old and all were less than 4 years old (Fig. 1). Figure 2 shows the monthly frequency of RSV patients 
over the one-year study period. One hundred and forty-four (97.1%) of the RSV patients were detected between 
May and October, with a clear peak between June and September, corresponding to 84.7% of annual RSV cases. 
Two RSV patients (1.3%) died.
One hundred and thirty-two (84.1%) RSV patients had pneumonia, which was significantly more frequent 
than in RSV-negative patients (64.2%, p < 0.001) (Table 2). When stratified by age group (Fig. 1A), no signif-
icant difference (p > 0.05) was observed, except for the 2 to <3-year-old group (87.5% with pneumonia in 
RSV-positive, 57.6% with pneumonia in RSV-negative, p = 0.035).
Severe pneumonia was negatively associated with RSV infection (40.7% of severe pneumonia in RSV-negative 
patients and 29.3% in RSV-positive patients, p = 0.014) (Table 2). When considering RSV patients with pneumo-
nia, the proportion of severe pneumonia (35%) was similar in all age groups (Fig. 1B), whereas in RSV-negative 
patients with pneumonia, severe pneumonia was associated with the one-year-old group (75.6%) in comparison 
to the other age groups (42.9–57.9%, p > 0.005, Fig. 1B).
Characteristics n (%)
 Human metapneumovirus 6 (1.6)
 Human adenovirus 28 (7.3)
 Human rhinovirus 70 (18.3)
Table 1. Baseline characteristics of ARI patients (n = 383). Data in the table are number of patients and 
percentages, except for a few variables for which the unit is specified. Because of missing values, superscript 
numbers indicate the number of patients for whom data were available. Low birth weight: defined by World 
Health Organisation as weight at birth less than 2,500 g31. Fever: defined as body temperature ≥38 °C per 
axilla32. Children less than 2 years old were defined as ‘PCV13 received’ if they had received: at least two doses of 
vaccine for children less than 1 year old or at least one dose of vaccine for children between 1 to 2 years old. Wet 
season: from May to October.
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Characteristics RSV-positive n (%) RSV-negative n (%)
OR (95% CI) p-valueNumber of patients 157 (41.0) 226 (59.0)
Demographics
 Age (months), median (IQR) 11 (4–18) 14 (6–27)
 Age groups
  Less than 1-month-old 10 (6.4) 4 (1.8) reference
  1 to less than 3-month-old 16 (10.2) 26 (11.5) 0.2 (0.06–0.9) 0.061
 3 –month-old to less than 1-year-old 56 (35.7) 65 (28.8) 0.3 (0.1–1.1) 0.09
  1 to less than 2-year-old 56 (35.7) 63 (27.9) 0.3 (0.1–1.2) 0.09
  2 to less than 3-year-old 16 (10.2) 33 (14.6) 0.2 (0.05–0.7) 0.013
  3 to less than 4-year-old 3 (1.9) 24 (10.6) 0.05 (0.01–0.3) <0.001
  4 to less than 5-year-old 0 (0.0) 11 (4.9) NA <0.001
 Gender (Male) 94 (59.9) 125 (55.3) 1.2 (0.7–1.8) 0.217
 Birth weight (g), median (IQR) 3,100 (2,700–3,400) 3,000 (2,700–3,300)
  Low birth weight347¥ 17 (12.1) 29 (14.0) 0.8 (0.4–1.6) 0.369
 Wards
  ICU 27 (17.2) 31 (13.7) 1.3 (0.7–2.2) 0.214
  Paediatric Infectious Disease 17 (10.8) 41 (18.1) 0.5 (0.3–1.0) 0.033
  General Paediatric 113 (72.0) 154 (68.1) 1.2 (0.7–1.8) 0.246
 Season (Wet season*) 144 (97.1) 112 (49.6) 11.2 (6.0–21.0) <0.001
 PVC 13 received268♯ 68 (57.1) 75 (50.3) 1.3 (0.8–2.0) 0.268
Clinical presentation
 Duration of illness prior to hospitalization (day), 
median (IQR) 4 (3–5) 3 (2–5)
 Fever documented at enrolment381 94 (60.6) 141 (62.4) 0.9 (0.6–1.4) 0.406
 Cough381 155 (99.4) 213 (94.7) 8.7 (1.1–67.9) 0.010
 Difficulty breathing375 134 (87.0) 141 (63.8) 3.8 (2.2–6.5) <0.001
 Coryza380 149 (95.5) 190 (84.8) 3.8 (1.6–8.8) 0.001
 Diarrhea372 75 (48.4) 80 (36.9) 1.6 (1.1–2.4) 0.017
 Conjunctival suffusion361 1 (0.7) 11 (5.1) 0.1 (0.02–0.9) 0.016
 Convulsions378 6 (3.9) 34 (15.2) 0.2 (0.09–0.5) <0.001
 Rigors328 6 (4.7) 28 (13.9) 0.3 (0.1–0.8) 0.005
 Vomiting374 93 (60.8) 115 (52.0) 1.4 (0.9–2.2) 0.058
Physical examination
 Chest indrawing378 115 (74.2) 101 (45.3) 3.5 (2.2–5.4) <0.001
 Nasal flaring371 43 (28.7) 43 (19.5) 1.7 (1.02–2.7) 0.027
 Lymphadenopathy359 2 (1.3) 19 (9.0) 0.1 (0.03–0.6 0.001
 Abnormal pulmonary auscultation366 137 (91.3) 121 (56.0) 8.3 (4.4–15.5) <0.001
 Tachypnea364 89 (58.9) 82 (38.55) 2.3 (1.5–3.5) <0.001
 Oxygen saturation<90% in room air342 17 (11.5) 30 (15.5) 0.7 (0.4–1.3) 0.184
 Rashes366 8 (5.4) 16 (7.4) 0.7 (0.3–1.7) 0.296
 Respiratory distress367 48 (32.7) 60 (27.3) 1.3 (0.8–2.0) 0.161
 Central cyanosis372 20 (13.2) 26 (11.8) 1.1 (0.6–2.1) 0.393
 Wheeze369 51 (33.6) 62 (28.6) 1.3 (0.8–1.9) 0.182
 Stridor365 3 (2.0) 13 (6.0) 0.3 (0.09–1.1) 0.053
 Grunting369 5 (3.4) 13 (5.9) 0.6 (0.2–1.6) 0.193
 Inability to drink368 17 (11.3) 28 (12.9) 0.9 (0.5–1.6) 0.380
 Prostration or lethargy368 9 (6.0) 18 (8.3) 0.7 (0.3–1.6) 0.263
Outcomes
 Pneumonia 132 (84.1) 145 (64.2) 2.9 (1.8–4.9) <0.001
 Severe pneumonia 46 (29.3) 92 (40.7) 0.6 (0.4–0.9) 0.014
 Length of stay ≤ 5 days 376 132 (85.2) 173 (78.3) 1.6 (0.9–2.8) 0.060
 Supplementary oxygen used378 29 (18.7) 40 (17.9) 1.1 (0.6–1.8) 0.476
 Death 2 (1.3) 3 (1.4) 0.9 (0.2–5.8) 0.666
Detection of:
 S. pneumoniae 98 (62.4) 115 (50.9) 1.6 (1.1–2.4) 0.016
 H. influenzae 84 (53.5) 120 (53.1) 1.0 (0.7–1.5) 0.510
Continued
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Coryza (95.5%), difficulty breathing (87.0%) chest indrawing (74.2%), and abnormal pulmonary auscultation 
(91.3%) were significantly associated with RSV infection in ARI patients as well as in ARI patients with pneumo-
nia (Table 2, Supplemental data Table S2).
Influenzavirus, Human parainfluenza virus, Human metapneumovirus, Human adenovirus, and Human rhinovirus 
were significantly more frequent in RSV-negative patients than in RSV-positive patients (p < 0.05), whereas, 
S. pneumoniae detection was significantly associated with RSV infection (p = 0.016) (Table 2). When strati-
fied by age group, this association was significant only for patients aged between 1 and <2 years old (p = 0.026, 
Supplemental data Figure S2). There was no apparent association between H. influenzae and RSV infection status.
Among the <2 year olds, half of the RSV patients (57.1%) had received PCV13, with a similar proportion 
observed in RSV-negative patients (50.3%, p = 0.268).
Predictive factors for severity. Predictive factors for severe pneumonia for all ARI patients, RSV-positive 
and RSV-negative patients were assessed using univariate followed by multivariable analyses (Supplemental 
Tables S3 to S5). Given that most of RSV patients were younger than 2 years old, the analyses were also performed 
within just this subgroup of patients (Supplemental data S6 to S8).
Age less than 3 months was the only factor that was independently associated with severe pneumonia in all 
patient groups (p ≤ 0.009).
Detection of Human adenovirus was associated with severe pneumonia in all ARI and RSV-negative patient 
groups but not in the RSV-positive patient group.
Presentation during the wet season (from May to October) was independently associated with severe pneu-
monia only in the all RSV-negative patient group (p = 0.024), and borderline in all ARI patient (p = 0.050).
In patients <2 years old, male gender was negatively associated with severe pneumonia in RSV-positive 
patients (p = 0.020), and ‘PCV13 received’ was protective against severe pneumonia in RSV-negative patients 
(p = 0.001).
Figure 2. Monthly detection rate of RSV in ARI patients.
Characteristics RSV-positive n (%) RSV-negative n (%)
OR (95% CI) p-valueNumber of patients 157 (41.0) 226 (59.0)
 Influenzavirus 1 (0.6) 28 (12.4) 0.05 (0.01–0.3) <0.001
 Human parainfluenza virus 3 (1.9) 34 (15.0) 0.1 (0.03–0.4) <0.001
 Human metapneumovirus 0 (0.0) 6 (2.7) NA 0.041
 Human adenovirus 6 (3.8) 22 (9.7) 0.4 (0.1–0.9) 0.021
 Human rhinovirus 12 (7.6) 58 (25.7) 0.2 (0.1–0.5) <0.001
Table 2. Characteristics of ARI patients positive for RSV in comparison to ARI patients negative for RSV. Data 
in the table are number of patients and percentages, except for a few variables for which the unit is specified. 
Because of missing values, superscript numbers indicate the number of patients for whom data were available. 
Low birth weight: defined by World Health Organisation as weight at birth less than 2,500 g31. Fever: defined as 
body temperature ≥38 °C per axilla32. Children less than 2 years old were defined as ‘PCV13 received’ if they 
had received: at least two doses of vaccine for children less than 1 year old or at least one dose of vaccine for 
children between 1 to 2 years old. Wet season: from May to October.
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Discussion
We report for the first time the epidemiological and clinical features of RSV infection in ARI patients in Laos. 
RSV was found to be the most frequent virus detected (41.0% of recruited ARI patients). In our study, 47.7% of 
children with pneumonia were infected by RSV. This finding is consistent with others studies performed in several 
countries in the region15–17.
RSV outbreaks are known to vary from year to year and according to geographical patterns. A peak of RSV infec-
tion (84.7%) was observed from June to September (Fig. 2), corresponding to the rainy season in Laos. This is con-
sistent with the association of RSV infection with the rainy season reported in studies elsewhere in the tropics15, 18, 19. 
The explanation for this consistent association is unclear. It could be directly related to climatic factors, such as 
increased humidity, or reflect changes in social behaviour which may enhance transmission8, 19. Recently, Paynter 
reported that the wet conditions of the tropical rainy season may encourage contact transmission of this virus by 
increasing the amount of virus on surfaces and by increasing virus survival in droplets on surfaces20. However, other 
patterns of RSV seasonality in tropical areas have been described. There were peaks of RSV-associated hospitalization 
observed during cool periods from 2011 to 2014 in Bangladesh21. Substantial differences in geography and climate 
are present in Laos, especially between the south and the north of the country, and therefore additional data, collected 
over several years and from different areas, are required to fully describe the seasonality of RSV infection in Laos.
Among RSV-positive patients, 84.1% had pneumonia, of which 35% had severe pneumonia, with no significant 
differences between age groups. A similar finding was reported in two studies of hospitalized patients in Thailand, 
in which RSV was the viral pathogen most commonly associated with pneumonia in children under 5 years old15, 16. 
In Laos, pneumonia was less frequent in RSV-negative than in RSV-positive patients. However, severe pneumo-
nia was more frequent in RSV-negative patients (40.7%) than in RSV-positive patients (29.3%), especially in the 
children <1 year old, in whom the proportion with severe pneumonia was significantly higher in RSV-negative 
patients (62.1%, p < 0.001). The majority (87.9%) of RSV-positive patients were less than 2 years old. This is similar 
to the pattern of RSV epidemiology in children worldwide22–24 and makes this age group an important target for 
interventions such as vaccination, which might significantly reduce the incidence of pneumonia.
PCV13 vaccination was launched in Vientiane in November 2013, just one month before the beginning of our 
study. Therefore, it is highly unlikely to see the impact of PCV on pneumonia with such a small cohort and only 
1 year post vaccine introduction.
A low mortality was observed in both RSV-positive (1.3%) and RSV-negative (1.4%) patients. All five deaths 
were in the group with severe pneumonia, and four cases occurred in children less than one year old. This mor-
tality is lower than the estimate of 3% to 9% associated with RSV infection reported by Nair et al.25. Beliefs and 
practices when death is approaching are different in each country. In Southeast Asian culture, relatives usually 
wish children that they expect to die, to die at home26. This belief leads to discharge just before death, and hence 
may be a reason for the low apparent mortality rate in this study.
S. pneumoniae is also an important cause of respiratory tract infections. A synergistic interaction between RSV 
and S. pneumoniae has been proposed, either through the viruses rendering the epithelium more susceptible to 
bacterial colonization and inducing changes in immune function that might be favourable to bacterial invasion, 
or by bacterial colonization enhancing respiratory virus infections27, 28. In this study, S. pneumoniae was detected 
in a high proportion of RSV-positive patients (62.4%), but the association of S. pneumoniae with RSV infection 
was significant only in the 1 to <2-year-old age group (p = 0.026).
Co-detection of RSV and Human rhinovirus, Human adenovirus, Influenzavirus, or Human parainfluenza 
virus was infrequent, and Human metapneumovirus was not detected in any RSV-positive patients whereas they 
were found in RSV-negative patients. This finding suggests mutual exclusion of respiratory viruses for concomi-
tant infections, as proposed by Pascalis et al. for Influenzavirus29.
In a multivariable logistic model to analyse the predictive factors for severity, age <3 months was inde-
pendently associated with severe pneumonia in ARI patients, independent of RSV infection. This is consistent 
with other studies, confirming the vulnerability of this age group to severe respiratory infections. This is probably 
due to the immaturity of the young infant’s immune system, with low levels of cellular immunity and sub-optimal 
antibody responses30. The low overall mortality observed in our study did not allow us to investigate predictive 
factors for mortality.
Limitations of the current study were that it was conducted only on hospitalized children, in a single hospital, 
and over a short period of time. Therefore, more extensive studies on RSV infections in Laos are required, over 
a longer period of time and at locations representative of Lao geographical diversity and socio-environmental 
conditions. A case-control study, as well as collection of comprehensive data on patient’s environments, would 
enable the identification of risk factors for RSV infection. A case-control study would also permit investigating 
asymptomatic microorganism carriage. Moreover, it would be interesting to look at the RSV types, to analyse the 
differences in demographic, clinical features and severity of illness between RSV-A and RSV-B.
Our study provides a baseline snapshot of RSV epidemiology in children hospitalized with ARI in Vientiane 
Capital. RSV is an important public health issue in Laos, and possibly underestimated. This study shows that RSV 
is likely to be a major cause of ARI and pneumonia in young hospitalized children in Laos. There is an urgent 
need to develop more extensive studies in Laos, both in hospitals but also in the community, in order to have 
better estimates of burden of RSV over the country and over time, in order to implement effective public health 
intervention programs.
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